Boston Scientific Corp.
Boston Scientific (BSX)
Overview
Boston Scientific is a global medical device company that designs, manufactures, and markets devices used to diagnose and treat a wide range of medical conditions, primarily through minimally invasive procedures. Headquartered in Marlborough, Massachusetts, the company was founded in 1979 and has grown into one of the largest medical technology companies in the world, competing across cardiology, cardiac surgery, neurology, endoscopy, urology, and related specialties. Boston Scientific is large and fast-growing: it generated $20.1 billion in net sales for fiscal year 2025 (up nearly 20% year-over-year) and employed roughly 59,000 people worldwide as of the end of 2025, following continued organic growth and several sizable acquisitions, including the roughly $15 billion acquisition of Penumbra announced in early 2026.
What They Do & How They Make Money
Boston Scientific makes money by designing, manufacturing, and selling medical devices — ranging from heart stents and pacemakers to endoscopy tools and urological implants — to hospitals, ambulatory surgical centers, and physicians, who use them in interventional (catheter-based, minimally invasive) procedures rather than traditional open surgery. Revenue is generated primarily through direct device sales and, increasingly, through capital equipment and recurring consumable/disposable sales tied to procedures performed with that equipment, which creates a durable revenue stream as installed devices and systems drive repeat purchases of compatible disposables. The company invests heavily in R&D and case-by-case clinical evidence generation, since new devices typically require regulatory approval (FDA clearance/PMA in the U.S., CE marking and equivalents abroad) and physician training/adoption before they generate meaningful sales; once adopted, physician and hospital switching costs (training, established workflows, procedural familiarity) help sustain revenue over multi-year device life cycles. Growth has also been substantially fueled by M&A — Boston Scientific regularly acquires smaller device makers and technology platforms (such as Baylis Medical, Axonics, and Penumbra) to add new procedures and therapeutic areas to its portfolio, then scales those products through its large existing global sales force and hospital relationships.
Business Segments
Boston Scientific reports two primary segments, Cardiovascular and MedSurg, with further disclosed sub-categories:
- Cardiovascular ($13.25 billion in FY2025 net sales, up 23.2% reported / ~21% organic): The company's largest and fastest-growing segment, covering interventional cardiology products (stents, angioplasty balloons, structural heart devices such as the Watchman left atrial appendage closure device and heart valve technologies), electrophysiology and cardiac rhythm management devices (pacemakers, defibrillators, ablation systems), and peripheral interventions (devices to treat vascular disease outside the heart). Strong momentum in structural heart and electrophysiology (including pulsed-field ablation) has driven outsized growth in this segment.
- MedSurg ($6.82 billion in FY2025 net sales, up 13.9% reported / ~7% organic): A collection of therapeutic-area businesses including Endoscopy ($2.92 billion — devices for gastrointestinal and pulmonary procedures), Urology ($2.71 billion — devices for urological and pelvic health conditions, bolstered by the 2024 Axonics acquisition in sacral neuromodulation), and Neuromodulation ($1.2 billion — devices such as spinal cord stimulators for chronic pain).
Competitors
- Cardiovascular: Medtronic, Abbott Laboratories, Edwards Lifesciences (particularly in structural heart/valves), and Johnson & Johnson (Abiomed, electrophysiology) are the primary rivals in stents, structural heart, rhythm management, and peripheral vascular devices.
- Endoscopy: Olympus and Medtronic are major competitors in gastrointestinal and minimally invasive surgical devices.
- Urology and Neuromodulation: Medtronic, Coloplast, and (in neuromodulation specifically) Abbott and Nevro compete for market share.
- Broader medical device landscape: Stryker and Johnson & Johnson MedTech compete across several of Boston Scientific's therapeutic areas, and specialized players like Penumbra (now being acquired by Boston Scientific) compete in neurovascular and thrombectomy devices.
Competitive Position
Boston Scientific's competitive advantages stem from a broad, diversified device portfolio spanning multiple therapeutic areas, a large direct sales force with deep physician relationships, strong clinical evidence generation capabilities, and consistent execution on both organic innovation and disciplined tuck-in and larger-scale M&A. Its leadership positions in high-growth categories — notably left atrial appendage closure (Watchman), pulsed-field ablation, and structural heart — have made Cardiovascular the primary engine of company-wide growth, outpacing peers like Medtronic and Abbott in several of these categories in recent years. The company's willingness to pursue large acquisitions (Axonics in urology/neuromodulation, and the pending Penumbra deal in neurovascular/thrombectomy) has both diversified its revenue base and added new avenues of growth beyond its legacy cardiology franchise. Key risks include regulatory and reimbursement pressure (device approval timelines, hospital purchasing budgets, and government/payer reimbursement rates directly affect adoption), product liability exposure (the company has faced substantial litigation and settlements historically, including transvaginal mesh cases), pricing pressure from group purchasing organizations and larger diversified competitors, and integration risk associated with its active M&A strategy. Boston Scientific's ability to sustain double-digit organic growth — guided at 10–11% for 2026 — while integrating recent large acquisitions will be a key determinant of whether it continues to outgrow the broader medical device industry.